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The circulating angiogenic factors vascular endothelial growth factor-A, interleukin-6 and the ﬁbrin D-dimer fragment were
measured in the mesenteric vein, the uterine vein, as well as in peripheral venous and arterial samples in 21 randomly selected
patients with operable colorectal, ovarian and cervical carcinoma. In addition, immunohistochemistry for vascular endothelial
growth factor-A and interleukin-6 was performed on colorectal tumours of such patients. Serum and plasma vascular
endothelial growth factor-A were not signiﬁcantly elevated in the vein draining the tumours, despite tumour cell expression of
vascular endothelial growth factor-A. Serum vascular endothelial growth factor-A is therefore not all tumour-derived. In
contrast, serum interleukin-6 was highly elevated in the draining veins in agreement with expression of interleukin-6 in the
cytoplasm of tumour cells. In the megakaryoblastic cell line MEG-01, the expression of vascular endothelial growth factor-A
was found to be regulated by interleukin-6. Thus, the higher platelet vascular endothelial growth factor-A load resulting in
higher serum vascular endothelial growth factor levels in cancer patients may partly result from an interleukin-6 mediated up-
regulation of the expression of vascular endothelial growth factor-A in the precursor of the platelet, i.e. the megakaryocyte.
We also conﬁrmed by immunohistochemistry that platelets adhere and aggregate on tumour endothelium. We propose that
interleukin-6 indirectly promotes tumour angiogenesis through its up-regulation of the vascular endothelial growth factor-A
load in platelets. In addition, the correlations found between peripheral venous interleukin-6 and peripheral venous ﬁbrinogen
and D-dimers levels, and the high D-dimer levels found in the draining vein of the tumour, in agreement with ﬁbrin deposits
found in the tumour stroma, suggest an important role for interleukin-6 in extra-vascular ﬁbrinogen metabolism. Our results
suggest a pivotal role for interleukin-6 in the intrinsic link between haemostasis and angiogenesis. This might be of importance
in the development of anti-angiogenic agents based on interference with haemostasis.
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Haemostasis and angiogenesis are tightly regulated physiological
processes involved e.g. in wound healing and deregulated in cancer
development (Carmeliet and Jain, 2000). Both may be critical in
three inter-related features of tumour progression, i.e. growth,
invasion and metastasis (Carmeliet and Collen, 1998).
Vascular Endothelial Growth Factor-A (VEGF-A) is one of the
most important positive mediators of angiogenesis. Tumour cells
as well as stromal cells express VEGF-A (Leung et al, 1989; Veik-
kola et al, 2000). VEGF-A not only regulates endothelial cell
migration, proliferation and survival, but is also known as Vascu-
lar Permeability Factor (VPF) because it enhances endothelial cell
permeability even more potently than histamine (Dvorak et al,
1995). VEGF-A also induces tissue factor on endothelium and
tumour cells, activating coagulation and ﬁbrin formation
(Mechtcheriakova et al, 1999). This is of primary importance for
angiogenesis and tumour growth (Nagy et al, 1989; 1995). High
serum levels of VEGF-A are predictive for tumour doubling time
in patients with colorectal cancer. Elevated levels nearly normalise
after resection of the primary tumour (Dirix et al, 1997). These
observations indicate that circulating levels of VEGF-A mirror
the ongoing growth process in tumours.
A nearly 10-fold higher serum than plasma VEGF-A level is
found in both cancer patients as in healthy persons (Banks et al,
1998), indicating that circulating VEGF-A is mainly blood cell
associated, in particular in platelets (Verheul et al, 1997; Salgado
et al, 1999; Gunsilius et al, 2000). High serum VEGF-A levels are
frequently encountered in cancer patients, the platelets of whom
indeed have a higher VEGF-A content compared with healthy indi-
viduals; a prognostic signiﬁcance is attributed to these levels
(Salven et al, 1999; O’Byrne et al, 2000). How VEGF-A is regulated
in platelets or in megakaryocytes in cancer patients is unclear, but
VEGF-A in epithelial cells is regulated by IL-6 (Cohen et al, 1996).
Platelet production is also regulated by IL-6 (Ishibashi et al, 1989).
The interstitial ﬁbrin matrix, formed by VEGF-A-mediated
tissue factor expression on tumour and endothelial cells, or by
shedding of cancer pro-coagulant proteins (Mielicki et al, 1990),
may further serve as a scaffold for endothelial cell migration and
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www.bjcancer.comproliferation (Contrino et al, 1997). In addition, ﬁbrin-(ogen)
degradation products have pro-angiogenic properties (Thompson
et al, 1985; Stirk et al, 2000). Remarkably, high ﬁbrinolytic deriva-
tives are one of the most frequent coagulation test abnormalities
encountered in the oncological setting (Edwards et al, 1987).
In the present work we measured the circulating factors VEGF
and IL-6 in veins draining the tumour in order to provide direct
evidence of tumour secretion of these factors. We further investi-
gated how platelets of cancer patients acquire a higher VEGF-A
content. We then analysed whether circulating ﬁbrin degradation
products, D-dimers, are derived from intra-tumoural activation
of haemostasis. We more speciﬁcally focused on the role IL-6 could
have in both increasing the VEGF-content in platelets as well as in
mediating ﬁbrin formation in tumours.
MATERIALS AND METHODS:
Patients
Two patients with cervical carcinoma (FIGO Ib), ﬁve with ovarian
carcinoma (FIGO III), two of them with extensive disease (FIGO
IIIc), and 14 with colorectal carcinoma (Dukes A–C), of which
four had extensive disease at the moment of surgery (Dukes D),
were scheduled for elective abdominal surgery. Exclusion criteria
were: previous, concurrent or non-resectable cancer, local or
systemic inﬂammatory disease. The following staging procedures
were performed: chest X-ray, bone scintigraphy, CT-scan and echo-
graphy of the liver. All patients received 0.3 mg fraxiparin
subcutaneously for prevention of deep venous thrombosis (DVT).
All routine precautions for prevention of DVT were taken.
Tissue
As part of the normal surgical resection procedure, of the main
tumour mass, a representative, full cross section of the tumour
sample surrounded by adjacent mucosa was taken from all patients
involved. The tissue was ﬁxed in buffered formalin and parafﬁn-
embedded. Five mm sections were cut and mounted on poly-L-lysine
coated slides. Successive sections were used for immuno-staining.
Blood coagulation tests
During the surgical procedure, blood sampling occurred simulta-
neously in the mesenteric or uterine vein as well as in the brachial
vein and brachial artery respectively. Plasma collection and
measurement of prothrombin time (PT), activated partial thrombo-
plastin time (aPTT), ﬁbrinogen, platelet counts and D-dimer levels
were performed as mentioned previously (Dirix et al, 2002).
Elisa
Angiogenic cytokines Blood sampling was performed as
mentioned above. Serum collection and VEGF-A165 and IL-6
measurements were performed as mentioned previously (Salgado
et al, 1999). Plasma VEGF-A165 was measured with an ELISA-kit
of R&D systems (R&D systems, Minneapolis, MN, USA) on triso-
dium citrate-anticoagulated collected blood. For the ELISA-assay of
VEGF-A165, no cross-reactivity with other members of the VEGF-A
family is documented. Samples were assayed in duplicate. Within
assay variability has been tested before (Salgado et al, 1999).
Immunohistochemistry
VEGF Immunohistochemistry was performed on colorectal
cancer tissue as described previously with the anti-VEGF-A VG-1
antibody that stains VEGF-A efﬁciently on parafﬁn sections (Turley
et al, 1998). This antibody recognises the 121, 165 and 189
isoforms of the VEGF-A protein.
IL-6 Deparafﬁnisation and quenching of endogenous peroxidase
was performed. The primary 1/10 diluted polyclonal anti-IL-6 anti-
body (Genzyme Co., Cambridge, MA, USA) was then applied on
sections of the colorectal carcinomas followed by a biotinylated
secondary antibody. Streptavidin conjugated with peroxidase was
subsequently applied on the sections (DAKO, Glostrup, Denmark).
Finally, amino-ethylcarbamazimine (AEC) was used as a substrate
reagent. Negative controls included the omission of the primary
antibody and the use of an irrelevant primary antibody.
Fibrin After deparafﬁnisation and quenching of endogenous
peroxidase, protein digestion was performed with protease. Slides
were placed on a Ventana NexES (Ventana Medical Systems,
Inc.) automated immunostainer and stained with a 1/100 diluted
monoclonal T2 G1 antibody (Acc. Chem. Sci. Corp., USA) over-
night at 48C. This antibody is speciﬁc for the peptide Ba 15-42
of ﬁbrin and for ﬁbrin II. Fibrin II is obtained after cleavage of
ﬁbrinogen by thrombin at the bond Aa 16-17 and Bb 14-15. Fibri-
nopeptides A and B are released after cleavage by thrombin.
Consequently, intact ﬁbrinogen was not stained (Kudryk and Bini,
2000). The staining was completed with a Vector Basic DAB detec-
tion kit (Ventana Medical Systems, Inc.). Negative controls
included the omission of the primary antibody. Parafﬁn embedded
placental tissue with peri-villous ﬁbrin deposits was used as a posi-
tive control.
Platelets Immunohistochemistry for platelet glycocalicin was
performed to demonstrate adherence and aggregation of platelets
on endothelium in colorectal tumours. Glycocalicin is a fragment
of the platelet membrane glycoprotein Ib (Steinberg et al, 1987).
Deparafﬁnisation and quenching of endogenous peroxidase was
performed. Normal rabbit serum (NRS), diluted 1/5, was applied,
followed by 1/20000 diluted primary mouse anti-human glycocali-
cin (clone: G28E5) antibody (kind gift from Dr Hoylaerts).
Subsequently, the 1/400 diluted, secondary biotinylated rabbit
anti-mouse antibody (DAKO, Glostrup, Denmark) was applied.
The immune reaction was completed with ABC-streptavidin detec-
tion system and DAB (diaminobenzidine) as chromogen. The slides
were counterstained with haematoxylin and mounted. Negative
controls included the omission of the primary antibody, the addi-
tion of an irrelevant primary antibody directed against glucose-
oxidase from Aspergillus Niger species (this enzyme is not inducible
in mammalian cells) and parafﬁn embedded normal endometrium
tissue. Positive controls included staining of platelets in parafﬁn
embedded thrombus and placenta with prominent ﬁbrin deposits
as well as in a platelet pellet.
Cell culture experiments
We used the human megakaryoblastic cell line MEG-01 to evaluate
whether IL-6 is able to modulate the expression of VEGF in mega-
karycocytes. Ogura and colleagues established the MEG-01 cell line
from a patient in a megakaryoblastic crisis of chronic myelogenous
leukaemia. This cell line possesses many megakaryocytic speciﬁc
markers and does not posses any marker of B-cells, T-cells and
myeloid cells (Ogura et al, 1985).
The MEG-01 cell line has the receptor for IL-6 and blocking IL-
6 with anti-IL-6 antibodies did not have any signiﬁcant effects on
cell growth (Kellar et al, 1995). In order to conﬁrm this we
analysed with the Alamar blue assay (Trek Diagnostics, USA)
whether alterations in cell proliferation occur after adding IL-6
(10 and 100 ng ml
71) to the culture medium. The cells were
cultured in Iscove’s modiﬁed Dulbecco‘s medium (IMDM), with
10% foetal calf serum and antibiotics. The experiments were
initiated by seeding 5610
4 cells well
71 in a 24-well plate and
allowed to proliferate for 24 h in 10% FCS medium before adding
10 or 100 ng ml
71 IL-6 in addition with 1/10 diluted Alamar blue
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
A role for IL-6 in haemostasis and angiogenesis in cancer
R Salgado et al
1438
British Journal of Cancer (2002) 87(12), 1437–1444 ã 2002 Cancer Research UKmedium. Fluorescence intensities, as a measure of reduction of the
Alamar blue medium by proliferating cells, was measured every 6 h
with a Cytoﬂuor (Cytoﬂuor
TM 2300, Millipore).
In subsequent experiments the IL-6 receptor (IL-6R) was
blocked for 48 h with a molar excess of monoclonal anti-IL-6R
antibody (20 mgm l
71) (R&D Systems, Minneapolis, MN, USA).
Cells without antibody served as negative controls.
Cell viability was assessed using Trypan blue exclusion dye.
Conditioned medium was collected and ELISA for VEGF-A was
performed. Experiments were performed in triplicate.
Ethical committee
The local Ethical Committee approved this study and informed
consent was obtained from all patients involved.
Statistical analysis
Statistical analysis was performed with Graphpad Prism, version
2.0 (Graphpad Software, Inc.). Half the detection limit value of
the patient samples was used for statistical analysis in case the
measured values did not reach the detection limit of the assay.
Detection limits were 0.7 pg ml
71 and 9 pg ml
71 for the IL-6
and VEGF-A assays, respectively. Comparisons of continuous vari-
ables were performed with the Mann–Whitney U-test. A paired
students t-test was used to evaluate observed differences in the cell
culture experiments. The relation between continuous variables
was analysed with a Spearman rank correlation analysis.
Means+standard deviations are given. A P-value 50.05 was
considered to be signiﬁcant.
RESULTS
Analysis of VEGF, IL-6 and D-dimers in patients without
distant metastasis
In order to verify whether there was a gradient for VEGF, IL-6 and
D-dimers between the afferent and efferent blood ﬂow in a tumour
we explicitely used samples from patients without distant metasta-
sis (n=15) as VEGF, IL-6 and D-dimers produced by metastases
could mask observed gradients. We also assumed that the values
in the brachial artery samples are comparable with mesenteric
and uterine artery samples. Mean age of all patients involved is
65.71+13.4 years.
VEGF-A, serum and plasma VEGF-A Seventy-ﬁve per cent of
all patients involved with colorectal cancer (n=14) had tumour cell
expression of VEGF-A (Figure 1A). We analysed in patients without
distant disease (n=15) whether tumour cell produced VEGF-A is
secreted in the main blood stream, accounting herewith for the high
serum VEGF-A levels found in cancer patients. None of the patients
had serum or plasma values below the detection limit of the assay. No
signiﬁcant differences were observed between serum VEGF-A in
arterial and mesenteric/uterine vein samples (345.2+269.5 pg ml
71
and 482.7+371.1 pg ml
71 respectively; P=0.77; Figure 2A: n=15;
Table 1). We compared plasma VEGF between arterial and mesen-
teric/uterine vein samples. Means of 30+15.28 pg ml
71 and
19.92+9.22 pg ml
71 were found for arterial and tumoural efferent
samples respectively (P=0.07; Figure 2B; n=15; Table 1).
Interleukin-6 All patients with colorectal cancer had extensive
IL-6 labelling in the tumour cell compartment (Figure 1B; n=14).
A 2.5-fold higher serum level of IL-6 was observed in the mesen-
teric/uterine vein compared with arterial samples (17.66+18.3 vs
7.06+9.8 pg ml
71; P50.001, Mann–Whitney U-test; Figure 2C;
n=15; Table 1). Only one patient had an IL-6 value below the
detection limit of the assay.
A correlation was observed between circulating IL-6
(6.9+9.7 pg ml
71), and platelet count in the peripheral venous
circulation in all patients without metastasis (r=0.54; P=0.04;
Figure 3A; n=15). Also, IL-6 correlates with circulating ﬁbrinogen
levels (r=0.69; P=0.005) and with D-dimers (r=0.69; P=0.006;
Figure 3B,C; n=15) in brachial vein samples.
Fibrinogen, ﬁbrin and D-dimers (n=15) Fibrinogen levels
were 357+76 mg dl
71 for the arterial samples, 354.1+87 mg dl
71
and 354.8+99.8 mg dl
71 for the venous peripheral and tumoural
draining vessels respectively (n=15). No statistical differences were
observed between ﬁbrinogen levels in the arterial and efferent
draining vein respectively (P=0.79; Table 1).
Mean D-dimer levels in the mesenteric/uterine vein were
1706+2603 ng ml
71, whereas in the brachial artery a mean value
of 798.1+638.1 ng ml
71 was found (P=0.08; Mann–Whitney U-
test; Figure 2D; Table 1; n=15). As already mentioned, both aPTT
and PT values were in the normal range indicating that the high D-
dimer levels encountered in the draining veins are not due to arti-
factual activation of coagulation during sampling.
The major substrate of D-dimers, ﬁbrin, was encountered both
in the stromal as well as on the luminal and/or abluminal side
of endothelial cells in the majority of cases examined (Figure
1D,E; n=14). No spatial co-localisation between platelet and ﬁbrin
staining was evident.
Platelets (n=15) Mean platelet count in the brachial vein,
brachial artery, and mesenteric/uterine vein were 254.4+60.16
10
3 ml
71, 253+68.2610
3 ml
71 and 241.9+60610
3 ml
71.N o
statistical differences were observed between platelet counts in
the arteria brachialis and efferent draining vein (Table 1; n=15).
Activated Partial Thromboplastin Time (APTT) en PT were in all
samples in the normal range indicating that no artifactual coagula-
tion occurred in the samples taken. To merely verify whether
platelet adherence and aggregation occurs in tumours we
performed immunohistochemistry using an antibody directed at
the platelet membrane protein glycocalicin. Positive staining indi-
cates that these platelets are activated since glycocalicin is
translocated to the platelet membrane upon activation.
The speciﬁcity of the glycocalicin platelet antibody was demon-
strated in the positive controls (platelets in a platelet pellet, in a
thrombus and in placental ﬁbrin deposits), where clear staining
of platelets was shown. Tumour cells, the ﬁbrin matrix in the
thrombus, white blood cells as well as in the placental ﬁbrin depos-
its stained negative. Platelet adherence and aggregation on
endothelial cells and extra-vasation of platelets was observed in
all tumours (Figure 1C; n=14).
Analysis of VEGF, IL-6 and D-dimers in patients with
distant metastasis
In order to ﬁnd evidence for IL-6 and D-dimer secretion by
metastatic cells we compared arterio-venous differences in the
primary tumour of patients with metastasis (n=6). If metastatic
cells would secrete both IL-6 as well as D-dimers, arterial levels
of these would increase and would consequently mask or lessen
the arterio-venous gradients as were observed in non-metastatic
patients. Mean age of all patients with metastasis involved is
62.8+9.2 years.
Interleukin-6
Arterial levels of IL-6 were compared in metastatic cancer patients
(n=6) were compared with arterial levels in non-metastatic patients
(n=15). Analysing IL-6 in those patients with extensive disease
elaborated about two-fold higher arterial IL-6 levels
(13.42+17.4 pg ml
71) than respectively encountered in those
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(12), 1437–1444patients without metastatic disease (7.06+9.8 pg ml
71). None of
the patients had IL-6 values below the detection limit of the assay.
Analogous results were obtained when comparing peripheral
venous samples (12.95+15.5 pg ml
71). When analysing arterio-
venous differences in these patients with a mean level of IL-6 of
80.20+129.9 pg ml
71 in the mesenteric/uterine vein, a P-value
of 0.09 compared with P50.0001 in the non-metastatic group
was found.
D-dimers
Arterial levels of D-dimer concentrations of patients with advanced
disease (n=6) were compared with non-metastatic patients (n=15).
A three-fold higher arterial D-Dimer level (2372+1741 ng ml
71)
was found in advanced metastatic patients compared with those
patients without metastatic disease (798.1+638.1 ng ml
71). Analo-
gous results are obtained when comparing peripheral venous
samples (2575+1870 ng ml
71). When analysing these arterial
levels with the D-dimers measured in the veins draining the
primary tumour in these patients (n=6; 3066+1741 ng ml
71), a
P-value of 0.69 compared with P=0.08 in patients without metas-
tasis was yielded.
Effect of IL-6 on VEGF-A secretion in the MEG-01 cell line
Cell viability exceeded 98% in all circumstances. The mean IL-6
and VEGF-concentrations (pg ml 1
71610
3 cells) in the condi-
tioned medium of the control cells were 2.84+2.084
pg ml 1
71610
3 and 6.093+2.651 pg ml 1
71610
3 cells, respec-
tively.
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Figure 1 (A) VEGF-immunoreactivity in colorectal tumour cells (arrows 6400). (B) Interleukin-6-immunoreactivity in colorectal tumour cells (arrow
6400). (C) Adherence, aggregation and extravasation of platelets (thin arrows) in the vicinity of colorectal tumour cells (thick arrows 6400). (D)
Intra-vascular immunostaining of ﬁbrin on endothelial cells (arrow 6400). (E) Extra-vascular stromal staining (thin arrows) of ﬁbrin near tumour cells (thick
arrow 6400).
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71
IL-6 yielded mean VEGF-values of 5.34+1.6 pg ml 1
71 and
4.72+0.6 pg ml 1
71610
3 cells, which were not signiﬁcantly
higher than the VEGF concentration in the conditioned medium
of control wells.
We then analysed with the Alamar blue assay whether blocking
of the IL-6 receptor resulted in a signiﬁcant inhibition of cell
proliferation. No signiﬁcant changes in cell proliferation were
observed (data not shown).
The median+s.e. (standard error) VEGF concentration after
48 h incubation with an IL-6R blocking antibody was
3.44+1.44 pg ml 1
71610
3 compared with 6.850+1.082
pg ml 1
71610
3 cells for the control cells (P=0.03) (Figure 4).
DISCUSSION
Interleukin-6 is a cytokine involved in haematopoietic cell differen-
tiation, in the regulation of the acute-phase response, in immune
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Figure 2 Observed gradients between arterial samples (art.) and tumour efferent blood (EV: efferent vene: mesenteric and uterine vene) for (A) serum
VEGF-A, (B) plasma VEGF-A, (C) Interleukin-6 and (D) D-dimers in patients with localised cervical, ovarian and colorectal cancer (n=15).
Table 1 Comparison between coagulation and angiogenesis factors in arteria brachialis, peripheral vein
and mesenteric/uterine vein in patients with non-metastatic cancer (n=15)
Arterial Peripheral venous Efferent P-value
a
Platelets 253.0+68.2 254.4+60.1 241.9+60.0 0.71
Fibrinogen 357.0+76 354.1+87 354.8+99.8 0.79
D-dimers 798.1+638.1 737.3+448.3 1706+2603 0.08
Plasma VEGF 30.0+15.28 24.6+24.6 19.92+9.22 0.07
Serum VEGF 345.2+269.5 373.6+403.1 482.7+371.1 0.77
IL-6 7.06+9.8 6.936+9.7 17.66+18.3 50.0001
Platelets: 610
3 ml
71; Fibrinogen: mg dl
71; D-dimers: ng ml
71; VEGF and IL-6; pg ml
71. Efferent: mesenteric of uterine
vein values.
aP-value: differences between arterial and efferent values.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(12), 1437–1444regulation and is produced by epithelial, bone marrow and blood
borne cells (Borden and Chin, 1994; Simpson et al, 1997; Hirano,
1999). Several studies have elaborated on the prognostic impact of
circulating IL-6. A poor prognosis has been consistently associated
with high levels of serum IL-6 in patients with renal cell, ovarian,
and prostate cancer (Ljungberg et al, 1997; Tempfer et al, 1997;
Nakashima et al, 2000). We have shown that high serum levels
of IL-6 have independent prognostic signiﬁcance in a series of 96
patients with metastatic breast cancer (data not shown). De Vita
et al (2001) have recently demonstrated, in univariate analysis, that
high circulating IL-6 levels are associated with reduced overall
survival and reduced time to disease progression in patients with
gastrointestinal cancer.
Our results demonstrate that circulating IL-6 is mainly derived
from the tumour in patients with colorectal, cervical and ovarian
cancer (Figure 2C). Moreover, arterial and peripheral venous circu-
lating levels of IL-6 are about two-fold higher in patients with
disseminated disease compared with arterial and peripheral venous
IL-6 levels of patients with localised disease. These higher levels
diminish the arterio-venous differences in the primary tumour of
the patients with metastatic disease. This suggests that metastasised
cells also produce and secrete IL-6. Nevertheless, to deﬁnitively
prove that metastases secrete Il-6, gradient studies need to be
performed. This study, however, will be difﬁcult to perform due
to technical and ethical reasons.
We have also demonstrated in this study that neither serum or
plasma VEGF-A levels are signiﬁcantly elevated in the vein draining
the tumour, despite a high tumour cell expression of VEGF-A
(Figure 2A,B). This contradicts the common notion that serum
VEGF-A is mostly derived from spill over of tumour cell produced
VEGF-A in patients with cancer. Landriscina et al (1998) also did
not ﬁnd signiﬁcantly higher serum levels of VEGF-A in mesenteric
blood compared with peripheral blood in patients with colorectal
cancer. This ﬁnding was recently conﬁrmed in patients with rectal
cancer (Werther et al, 2001). These observations suggest that serum
VEGF-A might be derived from other sources. However, it might
be possible that continuous spilling of tumour-derived VEGF in
the circulation might lead, especially considering the half-life of
VEGF-A of about 30 min (Eppler et al, 2002), to equivalent levels
of venous and arterial VEGF-A.
Several groups have conﬁrmed the role of platelets in the storage
of circulating VEGF-A (Verheul et al, 1997; Banks et al, 1998;
Salgado et al, 1999; Gunsilius et al, 2000; Salgado et al, 2001).
In a previous study we have shown that serum IL-6 correlates
not only with the platelet count (illustrating its thrombopoietic
property), with serum VEGF-A (illustrating the importance of
IL-6 in the regulation of VEGF-A), but also with the VEGF-A load
in platelets (Salgado et al, 1999). Since thrombopoietic cytokines,
such as thrombopoietin (TPO) and interleukin-3 (IL-3), enhance
VEGF-A expression in megakaryocytes, and, as is the case for
TPO, in parallel with megakaryocytic differentiation, we hypothe-
sised that IL-6 derived from primary tumour cells as well as
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Figure 3 Observed correlation analysis between peripheral venous serum IL-6 and (A) platelets, (B) D-Dimers and (C) ﬁbrinogen (n=15).
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Figure 4 Cell culture experiment in which VEGF-A is measured with
ELISA in the conditioned medium of MEG-01 cell lines treated with a
blocking antibody against the IL-6 receptor.
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in platelet progenitors much in the same manner (Imai et al, 1991;
Mohle et al, 1997; Bobik et al, 1998; Salgado et al, 1999).
Our in vitro data demonstrate that the endogenous production
of IL-6 in a megakaryocytic cell line, MEG-01, is substantially high.
The observation that adding IL-6 did not have any effect on VEGF-
A production, might suggest that the IL-6 receptors are already
maximally stimulated and saturated. We therefore opted for block-
ing this autocrine pathway with a molar excess of IL-6 receptor
blocking antibody. Our results indicate that VEGF-A production
is, at least partly, regulated by IL-6 (Figure 4).
We elaborate on an important role of tumour cell produced IL-
6 in the enhanced platelet VEGF-A load of cancer patients explain-
ing herewith the previously found correlation between serum IL-6,
VEGF-A and the VEGF-A load in platelets. Moreover, as we did
not ﬁnd higher serum or plasma VEGF-A levels in the efferent
blood vessel of tumours, the role of bone marrow, thus megakar-
yocyte-derived platelet VEGF-A, may contribute more to the total
serum VEGF-A than previously suspected. Salven et al (1999) have
shown that circulating leucocytes contribute only for 17% of the
total circulating VEGF in patients with cancer, conﬁrming herewith
the observations that the majority of blood VEGF is contained
within platelets (Benoy et al, 2002).
The biological signiﬁcance of a higher platelet VEGF-A load in
patients with cancer is not clear. Nevertheless, in patients with
cancer, a worse prognosis is associated with a high platelet
VEGF-A load (O’Byrne et al, 2000). Pinedo et al (1998) postulated
a role of platelets in promoting angiogenesis through local release
of pro-angiogenic molecules (e.g. VEGF-A, bFGF, PDGF). A net
pro-angiogenic effect has recently been demonstrated, although
platelets also contain anti-angiogenic proteins (TSP-1, PF-4)
(Verheul et al, 2000b).
In our study we have shown adherence, aggregation and extra-
vasation of platelets in tumours (Figure 1C). Adherence, aggrega-
tion and extra-vasation lead to activation of platelets, which is
invariably associated with consequent release of pro-angiogenic
molecules (e.g. VEGF-A) contained in the platelet a-granules
(Verheul et al, 2000a). Our results may therefore partly conﬁrm
the hypothesis postulated by Pinedo and colleagues.
Interleukin-6 is also known to modulate ﬁbrinogen expression
in hepatic cells. High circulating ﬁbrinogen levels are encountered
in cancer patients (Yamaguchi et al, 1998) and in this study we
conﬁrmed previously found correlations between serum IL-6 and
circulating plasma ﬁbrinogen and D-dimers (Dirix et al, 2002).
This suggests that tumour-produced IL-6 may induce ﬁbrinogen
expression in hepatic cells, herewith partly explaining the observed
correlations between high ciculating IL-6 levels and circulating
ﬁbrinogen levels (P=0.005; r=0.69; Figure 3C).
Fibrinogen is under normal conditions encountered only in
small quantities in the extra-cellular matrix of tumours. Tumour
vessels exhibit an enhanced, VEGF-A induced, vascular permeabil-
ity and kinetics of extravasation of several circulating proteins are
enhanced in cancer patients, e.g. ﬁbrinogen (Dvorak et al, 1984).
Recent evidence, however, demonstrates that tumour cells them-
selves produce ﬁbrinogen, which is consequently deposited in the
extra-cellular matrix (Rybarczyk and Simpson-Haidaris, 2000).
Fibrinogen is, in the pro-coagulant environment of the tumour
stroma, rapidly converted to ﬁbrin. Interleukin-6 is able to induce
tissue factor expression on e.g. monocytes and may therefore
contribute to the intra-tumoural activation of coagulation
(Neumann et al, 1997). Measuring the ﬁbrin degradation product
D-dimer in the efferent vessel draining the tumour indicates that
circulating D-dimer levels are also derived from intra-tumoural
ﬁbrinogen metabolism (Figure 2D). The borderline signiﬁcance
found (P=0.08) may probably gain signiﬁcant values if a higher
number of patients are involved and may also partly be explained
by the involvement of patients with different histology in our
study. However, our results conﬁrm previous ﬁndings of intra-
tumoural activation indicated by measuring D-dimers in veins
draining lung tumours (Kalweit et al, 2000). The higher arterial
and peripheral venous D-dimer levels encountered in patients with
extensive disease compared with non-metastatic patients, masking
observed arterio-venous gradients compared with non-metastatic
patients, suggest that ﬁbrinogen turnover also occurs in metastatic
deposits. We have detected ﬁbrin in metastatic skin deposits from
patients with breast cancer (unpublished data). The importance of
plasma D-dimers is illustrated by our previous ﬁnding that high
circulating D-dimer levels correlate with progression kinetics
(P50.0001), with tumour volume (P50.0001) and with reduced
overall survival in patients with metastatic breast cancer (Dirix et
al, 2002).
In conclusion, this study provides further evidence that IL-6
may be pivotal in haemostasis and angiogenesis associated with
cancer.
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